Condition: Prostate Cancer · Sponsor: Sophiris Bio Corp
The purpose of this study is to determine a safe, effective, and tolerable dose of PRX302 for the treatment of low to intermediate risk prostate cancer.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Vantage Health | Ocala, Florida, United States | — |
| Chesapeake Urology Associates | Baltimore, Maryland, United States | — |
| New York Urology Associates | New York, New York, United States | — |
| Baylor Scott & White Memorial Hospital and Clinic | Temple, Texas, United States | — |
| Princess Alexandra Hospital | Harlow, United Kingdom | — |
| Imperial College | London, United Kingdom | — |
| University College Hospital (UCLH) | London, United Kingdom | — |
| University Hospital Southampton | Southampton, United Kingdom | — |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03081481